(Reuters). -AstraZeneca’s COVID-19 anti-bodies was found to be effective in reducing the death rate in patients who are not hospitalized in a study that concluded on Monday.
The trial’s main objective was met when AZD7442 reduced 50% the chance of severe COVID-19 death in patients who were symptomatic for less than seven days.
“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca (NASDAQ:).
It stated that the company would discuss these data with healthcare authorities without further explanation.
AstraZeneca has also developed the drug cocktail to treat people who are not immune to COVID-19 vaccinations. The drug was approved by U.S regulators last week for use as prevention drugs.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.